Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: Roles of gut hormones and leptin

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1956-1964

  Chen, Chih Yen ^a   Tsai, Chang Youh ^b   Lee, Pui Ching ^a   Lee, Shou Dong ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Appetite; Body weight; Cachexia; Etanercept; Ghrelin; Glucose dependent insulinotropic polypeptide (GIP); Leptin; Rheumatoid arthritis (RA)

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCOSE; LEPTIN; LIPID; URIC ACID;

ADULT; APPETITE; ARTICLE; BLOOD LEVEL; BODY FAT; BODY MASS; BODY WEIGHT; CACHEXIA; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; HYPERURICEMIA; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; URIC ACID BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTIRHEUMATIC AGENTS; APPETITE; ARTHRITIS, RHEUMATOID; BODY COMPOSITION; BODY MASS INDEX; CACHEXIA; FEMALE; GASTROINTESTINAL HORMONES; HUMANS; IMMUNOGLOBULIN G; LEPTIN; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; WEIGHT GAIN;

EID: 84876738647     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319100014     Document Type: Article

References (48)

1. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-59.
2. Aeiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 2011; 17: 3141-54.
3. Bingham CO 3rd, Ince A, Haraoui B, et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009; 5: 1131-42.
4. Su KY, Lee HT, Chou CT, et al. Improvement of active rheumatoid arthritis after etanercept injection: a single-center experience. J Chin Med Assoc 2009; 72: 581-7.
5. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 1463-72.
6. Engvall IL, Elkan AC, Tengstrand B, et al. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 2008; 37: 321-8.
7. Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2001; 2: 269-72.
8. Lang CH, Frost RA. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care 2002; 5: 271-9.
9. Truyens C, Torrico F, Angelo-Barrios A, et al. The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol 1995; 17: 561-8.
10. Roubenoff R, Roubenoff RA, Ward LM, et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505-10.
11. Roubenoff R. Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century. Arthritis Res Ther 2009; 11: 108.
12. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
13. Chen CY, Asakawa A, Fujimiya M, et al. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009; 61: 430-81.
14. Grossberg AJ, Scarlett JM, Marks DL. Hypothalamic mechanisms in cachexia. Physiol Behav 2010; 100: 478-89.
15. Lee MS, Huang YC, Wahlqvist ML. Chewing ability in conjunction with food intake and energy status in later life affects survival in Taiwanese with the metabolic syndrome. J Am Geriatr Soc 2010; 58: 1072-80.
16. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
17. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint-counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
18. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
19. Lee WJ, Chen CY, Chong K, et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011; 7: 683-90.
20. Iyer SS, Boateng LA, Sales RL, et al. Effects of peanut oil consumption on appetite and food choice. Int J Obesity (Lond) 2006; 30: 704-10.
21. Flint A, Raben A, Blundell JE, et al. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000; 24: 38-48.
22. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010; 1: 1-5.
23. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-6.
24. Walsmith J, Abad L, Kehayias J, et al. Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 2004; 31: 23-9.
25. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007; 46: 1824-7.
26. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factoralpha treatment. J Rheumatol 2008; 35: 855-61.
27. Kremers HM, Nicola PJ, Crowson CS, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3450-7.
28. Yajnik CS, Yudkin JS. The Y-Y paradox. Lancet 2004; 363: 163.
29. Jonsson SW, Backman C, Johnson O, et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001; 28: 2597-602.
30. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006; 1069: 414-9.
31. Jamnitski A, Visman IM, Peters MJ, et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010; 69: 1929-33.
32. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75: 22-4.
33. Makovey J, Macara M, Chen JS, et al. Serum uric acid plays a protective role for bone loss in peri-and postmenopausal women: A longitudinal study. Bone 2013; 52: 400-6.
34. Karagiozoglou-Lampoudi T, Trachana M, Agakidis C, et al. Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity. Metabolism 2011; 60: 1359-62.
35. Binymin K, Herrick A, Carlson G, et al. The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis. J Inflamm Res 2011; 4: 61-6.
36. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Antitumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1644-6.
37. Ferraz-Amaro I, Arce-Franco M, Muñiz J, et al. Systemic blockade of TNF-β does not improve insulin resistance in humans. Horm Metab Res 2011; 4 3: 801-8.
38. Magiera M, Kopec-Medrek M, Widuchowska M, et al. Serum ghrelin in female patients with rheumatoid arthritis during treatment with infliximab. Rheumatol Int 2011 Dec 24 Open access, DOI 10.1007/S00296-011-2262-7.
39. Mackelvie KJ, Meneilly GS, Elahi D, et al. Regulation of appetite in lean and obese adolescents after exercise: role of acylated and desacyl ghrelin. J Clin Endocrinol Metab 2007; 92: 648-54.
40. Chen CY, Fujimiya M, Laviano A, et al. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc 2010; 73: 225-9.
41. Chen CY, Tsai CY. Ghrelin and motilin in the gastrointestinal system. Curr Pharm Des 2012; 18: 4755-65.
42. Rao RS, Kini S. GIP and bariatric surgery. Obes Surg 2011; 21: 244-52.
43. Daousi C, Wilding JP, Aditya S, et al. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol 2009; 71: 195-201.
44. DePaula AL, Macedo AL, Schraibman V, et al. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg Endosc 2009; 23: 1724-32.
45. Härle P, Sarzi-Puttini P, Cutolo M, et al. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 970-1.
46. Popa C, Netea MG, de Graaf J, et al. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009; 36: 724-30.
47. Derdemezis CS, Filippatos TD, Voulgari PV, et al. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol 2009; 23: 595-600.
48. Gunaydin R, Kaya T, Atay A, et al. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 2006; 99: 1078-83.